Drug intelligence / Profile preview

KTI-016

Development stage: Discontinued
Lead developer: Keros Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

KTI-016 is a **fully human monoclonal antibody** developed by **Keros Therapeutics** that is designed to bind and neutralize **activin receptor type-1**, also known as **ALK2**. By inhibiting ALK2 signaling, the antibody suppresses hepcidin production, a key regulator of iron homeostasis, and was being explored as a treatment for **anemias driven by elevated hepcidin**, including **iron-refractory iron deficiency anemia** and **anemia of inflammation**. Preclinical studies in cynomolgus monkeys showed substantial hepcidin lowering after administration, but the program has been reported as **discontinued**.

Targets

ACVR1 (Activin receptor type I)

Beyond the preview

Go deeper on KTI-016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KTI-016.

Explore the full profile